IN8bio Inc (INAB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.93-2.02%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · INAB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
INAB — divestiture
Dated 2026-06-01
Entry into a Material Definitive Agreement. On June 1, 2026, IN8bio, Inc. (the “ Company ”) entered into a Capital on Demand TM Sales Agreement (the “ Sales Agreement ”) with JonesTrading Institutional Services LLC (the “ Agent ”) with respect to an at the market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares (the “ Placement Shares ”) of its common stock, par value $0.0001 per share (the “ Common Stock ”), through or to the Agent…
Why it matters: IN8bio is loss-making, and cash fell from $21.9 million in March to $18.0 million in June.
Worry ifCash falls below $18.0 million, or the quarterly net loss rises above $4.8 million.
Less concerning ifCash stays at or above $18.0 million and the quarterly net loss stays at or below $4.8 million.
Why it matters: The data can test whether INB-619 depletes target B cells while keeping harmful signals low.
Supportive ifIN8bio reports animal data showing B-cell depletion and γδ T-cell growth, with low IL-6 and TNF-α.
Worry ifThe data miss B-cell depletion, show weak γδ T-cell growth, or show high IL-6 or TNF-α.
Why it matters: The update can show how the leukemia program is progressing after patient dosing.
Watch forIN8bio reports that INB-100 dosing is complete and shares follow-up data at a late-2026 medical meeting.
Also watch forIN8bio reports that dosing is not complete, the update is delayed, or the follow-up shows poor patient outcomes.
Why it matters: Repeat-dose patients had longer survival in the reported data. More follow-up can test whether that gap lasts.
Supportive ifA new update keeps repeat-dose median overall survival above the 13.2-month SOC figure. It shows no new severe safety signal.
Worry ifA new update puts median overall survival after repeat doses at 13.2 months or less. It may also report new severe safety issues.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$331 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $839 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,520 loss on $10,000 · 65.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: FDA feedback can clarify the next step for the GBM program. A clear path would support progress.
Supportive ifIN8bio reports FDA feedback that names a clear next step or study path for DeltEx in GBM.
Worry ifIN8bio reports no FDA feedback, or says the FDA requires more data before it can set a path.